Strides Arcolab to leverage API business in Shasun acquisition

By Dan Stanton

- Last updated on GMT

Related tags Pharmaceutical drug Pharmacology

Strides Arcolab to leverage API business in Shasun acquisition
The acquisition of Shasun Pharmaceuticals will add API production and contracting services to Strides Arcolab, and according to Shasun’s CEO no jobs will be lost.

In July during while discussing finance     ial results, CEO Arun Kumar told investors Strides Arcolab had no plans for any “large ticket acquisitions.”​ Two months on and the Indian drugmaker announced this week it was looking to acquire Shasun Pharmaceuticals for an estimated $200m​, creating a top 15 Indian pharma firm with joint revenues of over $400m.

“Since the divestment of our injectables business [Agila to Mylan for $1.6bn​ last year], Strides has refocused on its oral finished formulation business,”​ Kumar said announcing the deal which, he added, “accelerates our strategy and growth prospects by creating a larger scale, fully integrated, leading Indian pharma company with multiple growth drivers and synergies.”

The API business represents about 60% of Shasun’s income and the deal adds a portfolio of 43 commercialised drug master files (DMF) and a further 23 under development to Strides.

Shasun has a network of 12 manufacturing facilities with three US Food and Drug Administration (FDA) approved finished dose plants and two FDA approved active pharmaceutical ingredient (API) sites, all of which will be integrated into Strides’ existing business.

Furthermore, Abhaya Kumar, the Managing Director of Shasun, told “We have lots of spare capacity [in our API network]”​ which will be leveraged by Strides, and there will be no redundancies due to this deal. 

Along with approximately 2,100 workers, the deal also brings with it a CRAMS (Contract Research and Manufacturing Services) business and Kumar confirmed all existing supply agreements would continue. “No existing contracts will be hampered,”​ he told us.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us